Published in Int J Colorectal Dis on November 29, 2016
The role of hepatic enzymes in Crohn's disease. Int J Colorectal Dis (2017) 0.75
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol (2014) 3.43
Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol (2014) 3.24
European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis (2013) 3.01
Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol (2009) 1.77
Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol (2006) 1.71
Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol (2014) 1.66
Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol (2008) 1.52
Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol (2002) 1.49
Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol (2009) 1.36
Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut (1994) 1.15
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur J Gastroenterol Hepatol (1999) 1.10
Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis (2007) 1.07
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis (1997) 0.91
Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli & Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol (1998) 0.89
Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf) (2014) 0.87
Factors that contribute to hypertransaminasemia in patients with celiac disease or functional gastrointestinal syndromes. Clin Gastroenterol Hepatol (2013) 0.80
Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohn's disease? Inflamm Bowel Dis (2008) 0.79
Hepatobiliary disorders among naïve patients with ulcerative colitis in Upper Egypt. Arab J Gastroenterol (2012) 0.78